Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119508 · ClinicalTrials.gov registry record · Phase 2
Ipilimumab + Temozolomide in Metastatic Melanoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT01119508: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01119508 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01119508, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if combining ipilimumab and temozolomide can help to control metastatic melanoma. The safety of this drug combination will be studied. Researchers would also like to study how this therapy affects the levels of certain chemicals in the blood that are related to your immune system.
Interventions
- DRUG Ipilimumab
- DRUG Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-05 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119508
The ClinicalTrials.gov registry entry for NCT01119508 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01119508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119508 about?
NCT01119508 is a clinical study titled "Ipilimumab + Temozolomide in Metastatic Melanoma". The goal of this clinical research study is to learn if combining ipilimumab and temozolomide can help to control metastatic melanoma. The safety of this drug combination will be studied. Researchers would also like to study how this therapy affects the levels of certain chemicals in the blood that ...
What is the current status of trial NCT01119508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2010-05. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01119508?
The interventions under investigation include: Ipilimumab (DRUG), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT01119508?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.